(Q36806607)

16 August 2017

1 reference

title

Consent in Alzheimer's disease research: risk/benefit factors (English)

1 reference

16 August 2017

0 references

0 references

B Lynn Beattie

1

1 reference

16 August 2017

publication date

1 March 2007

1 reference

Canadian Journal of Neurological Sciences

16 August 2017

published in

1 reference

16 August 2017

volume

34 Suppl 1

1 reference

16 August 2017

page(s)

S27-31

1 reference

Lessons from the AN 1792 Alzheimer vaccine: lest we forget.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Substituted judgment: how accurate are proxy predictions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Proxy and surrogate consent in geriatric neuropsychiatric research: update and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

How does an Alzheimer's disease patient's role in medical decision making change over time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Understanding of informed consent by demented individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Addressing the ethical challenges of clinical trials that involve patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

How proxies make decisions about research for patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Current concepts and future prospects for Alzheimer disease vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Is there a future for vaccination as a treatment for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

Proxies' decisions about clinical research participation for their charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

7 January 2021

Full-spectrum proxy consent for research participation when persons with Alzheimer disease lose decisional capacities: research ethics and the common good

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

7 January 2021

Informed consent by proxy. An issue in research with elderly patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

7 January 2021

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

7 January 2021

Information and competency for consent to pharmacologic clinical trials in Alzheimer disease: an empirical analysis in patients and family caregivers

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

7 January 2021

Selection bias introduced by the informed consent process

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

7 January 2021

Immunotherapy as a therapeutic treatment for neurodegenerative disorders.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005527

7 January 2021

10.1017/S0317167100005527

Identifiers

DOI

1 reference

16 August 2017

1 reference